Abstract #1063
Multiparametric 3T prostate MRI in patients with elevated PSA and no previous biopsy
Ivan Jambor 1 , Esa Khknen 2 , Pekka Taimen 3 , Harri Merisaari 4 , Jani Saunavaara 5 , Kalle Alanen 6 , Branislav Obsitnik 7 , Heikki Minn 4 , Viera Lehotska 8 , and Hannu Aronen 1
1
Departement of Diagnostic Radiology,
University of Turku, Turku, Finland,
2
Department
of Surgery, Turku University Hospital, Turku, Finland,
3
Department
of Pathology, University of Turku, Turku, Finland,
4
Turku
PET centre, University of Turku, Turku, Finland,
5
Medical
Imaging Centre of Southwest Finland, Turku University
Hospital, Turku, Finland,
6
Department
of Pathology, Turku University Hospital, Turku, Finland,
7
Department
of Urology, St. Elisabeth Oncology Institute,
Bratislava, Slovakia,
8
Department of
Radiology, St. Elisabeth Oncology Institute, Bratislava,
Finland
Fifty-five patients with elevated PSA (>4 ng/ml), no
previous biopsy and low risk of prostate cancer (PCa)
underwent mpMRI at 2 institutions (41 at institution A
and 14 patients at institution B), consisting of
anatomical T2-weighted imaging (T2wi), diffusion
weighted imaging (DWI), proton magnetic resonance
spectroscopy and dynamic contrast enhanced MRI, using
surface array coils followed by MRI targeted TRUS-guided
biopsy in addition to 12 core systematic biopsy. The use
of T2wi+DWI was shown to be an accurate tool for initial
decision management and targeting biopsy in patients
with elevated PSA.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
